BRIEF-Neurocrine Biosciences Announces Publication Of Landmark Narrative Review On FDA-Approved Vmat2 Inhibitors Demonstrating Unique Profile Of Ingrezza® (Valbenazine) Capsules

Reuters11-20

Neurocrine Biosciences Inc NBIX.O:

NEUROCRINE BIOSCIENCES ANNOUNCES PUBLICATION OF LANDMARK NARRATIVE REVIEW ON FDA-APPROVED VMAT2 INHIBITORS DEMONSTRATING UNIQUE PROFILE OF INGREZZA® (VALBENAZINE) CAPSULES

Source text: ID:nPnbNnBSBa

Further company coverage: NBIX.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584132773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584132773","market":"us","top_or_hot":-1,"title":"BRIEF-Neurocrine Biosciences Announces Publication Of Landmark Narrative Review On FDA-Approved Vmat2 Inhibitors Demonstrating Unique Profile Of Ingrezza® (Valbenazine) Capsules","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Neurocrine Biosciences Announces Publication Of Landmark Narrative Review On FDA-Approved Vmat2 Inhibitors Demonstrating Unique Profile Of Ingrezza® (Valbenazine) Capsules</title></head><body><p>Neurocrine Biosciences Inc <span>NBIX.O</span>:</p><ul><li><p>NEUROCRINE BIOSCIENCES ANNOUNCES PUBLICATION OF LANDMARK NARRATIVE REVIEW ON FDA-APPROVED VMAT2 INHIBITORS DEMONSTRATING UNIQUE PROFILE OF INGREZZA® (VALBENAZINE) CAPSULES</p></li></ul><p>Source text: <span>ID:nPnbNnBSBa</span></p><p>Further company coverage: <span>NBIX.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neurocrine Biosciences Announces Publication Of Landmark Narrative Review On FDA-Approved Vmat2 Inhibitors Demonstrating Unique Profile Of Ingrezza® (Valbenazine) Capsules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neurocrine Biosciences Announces Publication Of Landmark Narrative Review On FDA-Approved Vmat2 Inhibitors Demonstrating Unique Profile Of Ingrezza® (Valbenazine) Capsules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 21:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Neurocrine Biosciences Announces Publication Of Landmark Narrative Review On FDA-Approved Vmat2 Inhibitors Demonstrating Unique Profile Of Ingrezza® (Valbenazine) Capsules</title></head><body><p>Neurocrine Biosciences Inc <span>NBIX.O</span>:</p><ul><li><p>NEUROCRINE BIOSCIENCES ANNOUNCES PUBLICATION OF LANDMARK NARRATIVE REVIEW ON FDA-APPROVED VMAT2 INHIBITORS DEMONSTRATING UNIQUE PROFILE OF INGREZZA® (VALBENAZINE) CAPSULES</p></li></ul><p>Source text: <span>ID:nPnbNnBSBa</span></p><p>Further company coverage: <span>NBIX.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NBIX","symbol_name":"神经分泌生物科学","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA2ZX1GX:1","article_id":"2584132773","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584132773","pubTimestamp":1763646886,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Neurocrine Biosciences Announces Publication Of Landmark Narrative Review On FDA-Approved Vmat2 Inhibitors Demonstrating Unique Profile Of Ingrezza (Valbenazine) CapsulesNeurocrine Biosciences I","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NBIX":"神经分泌生物科学","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"简介-Neurocrine Biosciences宣布发布有关FDA批准的Vmat2抑制剂的具有里程碑意义的叙述性综述，展示了Ingrezza的独特特征®（缬苯那嗪）胶囊","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":0.9},"content_text":"BRIEF-Neurocrine Biosciences Announces Publication Of Landmark Narrative Review On FDA-Approved Vmat2 Inhibitors Demonstrating Unique Profile Of Ingrezza® (Valbenazine) CapsulesNeurocrine Biosciences Inc NBIX.O:NEUROCRINE BIOSCIENCES ANNOUNCES PUBLICATION OF LANDMARK NARRATIVE REVIEW ON FDA-APPROVED VMAT2 INHIBITORS DEMONSTRATING UNIQUE PROFILE OF INGREZZA® (VALBENAZINE) CAPSULESSource text: ID:nPnbNnBSBaFurther company coverage: NBIX.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584132773","isCrawlerRequest":true}